Dr. Reddy’s Laboratories (NYSE: RDY) announced today that Azacitidine
for Injection 100 mg/vial, a bioequivalent generic version of VIDAZA®
(azacitidine for injection), is approved by the United States Food
& Drug Administration (USFDA) on September 16, 2013. The launch of
product in the market is planned in the near-term.
The VIDAZA® brand had U.S. sales of approximately $378.5
Million for the most recent twelve months ending July 2013 according to
IMS Health.
Dr. Reddy’s Azacitidine for Injection 100 mg/vial is available in
single-use vials.
Disclaimer
This press release includes forward-looking statements, as defined in
the U.S. Private Securities Litigation Reform Act of 1995. We have based
these forward-looking statements on our current expectations and
projections about future events. Such statements involve known and
unknown risks, uncertainties and other factors that may cause actual
results to differ materially. Such factors include, but are not limited
to, changes in local and global economic conditions, our ability to
successfully implement our strategy, the market acceptance of and demand
for our products, our growth and expansion, technological change and our
exposure to market risks. By their nature, these expectations and
projections are only estimates and could be materially different from
actual results in the future.
About Dr. Reddy's
Dr. Reddy’s Laboratories Ltd. (NYSE: RDY) is an integrated global
pharmaceutical company, committed to providing affordable and innovative
medicines for healthier lives. Through its three businesses –
Pharmaceutical Services and Active Ingredients, Global Generics and
Proprietary Products – Dr. Reddy’s offers a portfolio of products and
services including APIs, custom pharmaceutical services, generics,
biosimilars and differentiated formulations. Major therapeutic focus is
on gastro-intestinal, cardiovascular, diabetology, oncology, pain
management and anti-infective. Major markets include India, USA,
Russia-CIS and Europe apart from other select geographies within
Emerging Markets.
VIDAZA® is a registered trademark of Celgene
Corporation.
IMS National Sales Perspectives: Retail and Non-Retail
MAT July 2013
Copyright Business Wire 2013